C Lekutis
Overview
Explore the profile of C Lekutis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lekutis C, Ferguson D, Grigg M, Camps M, Boothroyd J
Int J Parasitol
. 2001 Sep;
31(12):1285-92.
PMID: 11566296
Toxoplasma gondii is an obligate intracellular protozoan parasite with an exceptionally broad host range. Recently, it has become apparent that the number of surface antigens (SAGs) it expresses may rival...
2.
Hehl A, Lekutis C, Grigg M, Bradley P, Dubremetz J, Ortega-Barria E, et al.
Infect Immun
. 2000 Nov;
68(12):7078-86.
PMID: 11083833
Proteins with constitutive or transient localization on the surface of Apicomplexa parasites are of particular interest for their potential role in the invasion of host cells. We describe the identification...
3.
Lekutis C, Ferguson D, Boothroyd J
Exp Parasitol
. 2000 Oct;
96(2):89-96.
PMID: 11052867
Previous studies have shown the surface of Toxoplasma gondii to be dominated by a family of proteins closely related to SAG1. In this study, we report the existence of a...
4.
Kuroda M, Schmitz J, Lekutis C, Nickerson C, Lifton M, Franchini G, et al.
J Virol
. 2000 Aug;
74(18):8751-6.
PMID: 10954578
A tetrameric recombinant major histocompatibility complex (MHC) class II-peptide complex was used to quantitate human immunodeficiency virus type 1 (HIV-1) envelope (Env)-specific CD4(+) T cells in vaccinated and in simian/human...
5.
Lekutis C, Letvin N
J Virol
. 1998 Jun;
72(7):5840-4.
PMID: 9621044
It has been suggested that the inability of the immune response to control human immunodeficiency virus type 1 (HIV-1) replication may be due, at least in part, to the capacity...
6.
Letvin N, Montefiori D, Yasutomi Y, Perry H, Davies M, Lekutis C, et al.
Proc Natl Acad Sci U S A
. 1997 Aug;
94(17):9378-83.
PMID: 9256490
It is generally thought that an effective vaccine to prevent HIV-1 infection should elicit both strong neutralizing antibody and cytotoxic T lymphocyte responses. We recently demonstrated that potent, boostable, long-lived...
7.
Lekutis C, Letvin N
J Immunol
. 1997 Aug;
159(4):2049-57.
PMID: 9257873
The HIV-1 envelope (Env)-specific Th cell response of rhesus monkeys infected with nonpathogenic chimeric simian/human immunodeficiency viruses (SHIV) was assessed at a molecular level by establishing rgp120-specific CD4+ T cell...
8.
Lekutis C, Shiver J, Liu M, Letvin N
J Immunol
. 1997 May;
158(9):4471-7.
PMID: 9127013
The Th cell response elicited by an HIV-1 env plasmid DNA vaccine was assessed in rhesus monkeys by isolation of gp120-specific, MHC class II-restricted CD4+ T cell lines from PBL...
9.
Reimann K, Li J, Voss G, Lekutis C, Tenner-Racz K, Racz P, et al.
J Virol
. 1996 May;
70(5):3198-206.
PMID: 8627800
To explore the roles played by specific human immunodeficiency virus type 1 (HIV-1) genes in determining the in vivo replicative capacity of AIDS viruses, we have examined the replication kinetics...
10.
Yasutomi Y, Robinson H, Lu S, Mustafa F, Lekutis C, Arthos J, et al.
J Virol
. 1996 Jan;
70(1):678-81.
PMID: 8523593
In view of the growing evidence that virus-specific cytotoxic T lymphocytes (CTL) play an important role in containing the early spread of human immunodeficiency virus type 1 (HIV-1) in infected...